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CBCT in cervical cancer
Image guidance
Organ motion
a b s t r a c t
The contribution of Image-guided Radiotherapy (IGRT) to modern radiotherapy is undeni-
able, being the way to bring into daily practice the dosimetric benefits of Intensity-Modulated
Radiotherapy (IMRT). Organ and target motion is constant and unpredictable at the pelvis,
thus posing a challenge to the safe execution of IMRT. There are potential benefits of IMRT
in the radical treatment of cervical cancer patients, both in terms of dose escalation and
decrease of toxicity. But it is essential to find IGRT solutions to control the aspects that can
lead to geographic miss targeting or organs at risk (OAR) overdose. This review seeks to
describe the problems and possible solutions in the clinical implementation of IMRT/IGRT
protocols to treat intact cervical cancer patients.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
Cervical cancer is a common cause of consultation in Radio-
therapy and Oncology facilities around the world. According
to Global Cancer Observatory 2012, it is the fourth lead-
ing cause of cancer in women with an annual incidence of
527,000 cases and 265,000 deaths.1 Most patients with cer-
vical cancer are young women under 50 years of age that
are diagnosed at a locally advanced stage.2,3 Nowadays, a
concomitant treatment of radiotherapy/chemotherapy is con-
sidered the standard treatment for cervical cancer, due to
its effectiveness in terms of local control and survival rate.
Nonetheless, there are still many challenges to face for this
type of approach, specifically in the radiotherapy field. Hence,
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cutting-edge research in radiotherapy focuses on the potential
of radiation to effectively deal with this disease.
Intensity-Modulated Radiotherapy (IMRT) is a technique
able to achive better conformity and dose distribution than 3D
conformal techniques. These characteristics make it an ideal
approach to reduce organs at risk (OAR) exposition improving
toxicity outcomes, or to intensify doses at target to improve
local control.4,5 However, there is still some uncertainty as
to its reproducibility on a daily basis and how it could affect
clinical results.
Targets and organs motion are the enemies to beat in
implementing IMRT as a standard treatment in cervical
cancer patients. Pelvic anatomy is complex and comprises
several organs and structures with unpredictable and non-
orchestrated movements. Additionally, in order to obtain the
best oncological results, volumes to treat have to involve
not only the macroscopic tumor and cervix, but also the
uterus, parametrial tissue, vaginal-paravaginal tissue and
lymph node regions at risk. All these together pose a challenge
to get a reasonable safety margins, enough to cover the tar-https://doi.org/10.1016/j.rpor.2018.05.002
1507-1367/© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
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get and its variations, but not too large as otherwise IMRT
advantages could be lost.
Image-guided Radiotherapy (IGRT) is an indispensable
tool to control/minimize the treatment uncertainties and
reduce the risks of target miss and/or OAR overdose during
radiotherapy delivery. Defined as three-dimensional follow-
up with imaging before, during and/or after radiotherapy
administration,6 it is at this time the way to bring to daily
practice the dosimetric benefits of IMRT. For pelvic radio-
therapy, the contributions are huge and it is becoming a
requisite to subject patients to this technique. There are
many IGRT systems in the market, each with a different
guidance solution, but all are able to perform 3D following
and not just 2D verification. Thus, choosing one or another
depends on facility experiences, needs and resources. Per-
haps, the most widely used and growing IGRT option in clinics
is the cone beam computed tomography or CBCT. This is an
in-room tomography imaging employing kilovoltage X-rays
capable of showing not only bone or fiducial markers but
also soft tissue, and carrying out a comparison on-line/on-site
between acquired images and tomography images used for
planning.
This review seeks to describe the problems and the pos-
sible solutions in the clinical implementation of IMRT/IGRT
protocols to treat intact cervical cancer patients.
2. Problem description
The accuracy of IMRT delivery is affected by volume contour-
ing, set-up errors and inter-/intra-fraction organ movements
and deformation. Although all these aspects are important,
the most relevant in cervical cancer is target and organ
motion. The pelvic organs move continuously for many rea-
sons mainly because of variations in the bladder and rectum
filling (Fig. 1, DICOM files). These changes may result in
variations in the clinical target volume, so the selection of
appropriate contours and margins is mandatory.
Guidelines have been developed for delineation in cervix
cancer in an attempt to unify the target volumes. In addition to
gross tumor volume (GTV), the volumes to treat should include
areas at risk. Thus, the components of clinical target volume
(CTV) include the GTV, cervix, uterus, upper vagina, parame-
trial tissue and relevant draining nodal groups (common,
internal and external iliac, obturator, presacral and para-aortic
lymph nodes if affected).7
After defining CTVs, we must set up an internal target vol-
ume (ITV) as a margin to CTV that includes the variation for
organs and target movements. Defining the CTV motion is a
complex task. Three events are decisive and should be known
to find the ideal ITV: 1. Target motion, 2. OAR variation, and 3.
reduction in tumor volume and shape deformation.
2.1. ITV considerations
2.1.1. Target motion
Cervix: Knowing the tumor and cervix motion and shrinkage
is essential to avoid geographic miss and/or OAR overdose
during radiotherapy. Several authors have used different tools
to measure cervical movement, mainly images during treat-
ment and fiducial markers. In 2004, Lee et al. analyzed the
changes in the position of the cervix implanting a sleeve and
following it through portal images. The medial-lateral (ML),
superior–inferior (SI) and anterior-posterior (AP) displace-
ments were 10, 8 and 16 mm, respectively, with maximum
position change of 24, 36, and 23 mm, respectively.8 Another
report came from Chan et al. in 2008 who performed a compar-
ison of pre-determined points-of-interest in serial magnetic
resonance images (MRI). In that study, the movement of the
external cervix oscillated between 10 and 15 mm, suggesting
that daily images should be used to capitalize the benefits
of high-precision radiation in patients with cervical cancer.9
Also Jadon et al. systematic review reported greater cervical
movement in the AP and SI directions, with less ML displace-
ment. The means of motion in this review varied from 2.3 to
16 mm in the AP 2.7 to 8 mm in the SI and 0.3 to 10 mm in
the ML directions.10 A more recent analysis was presented
by Langerac et al. After implanting fiducial markers in fornix,
they compared the planning CT and the daily CBCTs searching
for variations, mean shifts of 0.4 mm, 1.0 mm and −3.9 mm for
the ML, AP, and SI directions were found, respectively. An addi-
tional comparison between the first CBCT scan and the daily
CBCTs was made, mean shifts were 0.8, 0.6 and −1.3 mm in ML,
AP, and SI directions, respectively.11 These degrees of move-
ments must be taken into account to define optimal margins,
since close margins can produce under-dosing of GTV/CTV or,
in contrary, over-dosing of OAR if larger margins are used.12
Lim et al. postulated that a possible reason for cervix
movement is the variation in the uterus position during the
treatment because of the tumor regression.13 This helps to
understand the movement of the cervix after 2–3 weeks
of treatment, but does not explain the changes that occur
daily (interfraction motion) or during the treatment session
(intrafraction motion). An explanation for both-inter and
intra-fraction motion – has been offered by several authors: a
direct correlation between the changes in the filling volumes
of the rectum and the bladder and the position and motion of
the cervix.9,10,14,15 A description of this phenomenon is offered
below.
Although interfraction motion is more relevant and larger,
a range of intrafraction motions has been also reported.
Yamamoto et al. reported their experiences using real-time
tumor tracking with fluoroscopy to measure intrafraction
movements of the cervix showing ranges from 1.4 to 4.2 mm.
That is not insignificant and should also be considered in the
choice of margins. In fact, margins of 5 mm at the body and
4 mm at the cervix have been proposed to encompass 95% of
the intrafraction motion.16
Uterus: Uterine motion is probably the most unpredictable
factor in pelvic radiotherapy. It can change completely in all
directions – rotation included – with also changes in shape
and size. This motion is not normally correlated with the
displacement of the cervix and is almost always influenced by
changes in bladder volume. In 2008 Taylor et al. assessed inter-
fractional uterine motions in gynecological cancer patients,
comparing 2 sets of MRI performed in two consecutive days.
Differences in the position of the uterine body of 7 mm (±9.0)
in the AP direction, 7.1 mm (±6.8) SI and 0.8 mm (±1.3) ML
were found, indicating that large movements of the uterus
may occur, particularly in the SI and AP directions.17 In 2010
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Fig. 1 – Changes on uterine and cervix position with bladder filling (uterus in magenta; GTV and cervix in red; bladder in
yellow; rectum in brown). The first figure shows the uterine and cervical position at planning, with a bladder volume of
122 ml. The second figure shows adaptive planning of the same patient. A reduction in tumor size and a change in bladder
volume (420 ml) is shown. The uterine position has moved both inferiorly and posteriorly significally.
Collen et al. observed through megavoltage computed tomog-
raphy (MVCT) that uterine deviations in all directions were
greater compared to those of the cervix. During treatment,
this movement was limited to mean shifts of 3.3 ± 11.9 mm for
the anterior direction, 0.3 ± 11.7 mm for the posterior direc-
tion, 0.7 ± 8.1 mm for the left lateral direction, −0.6 ± 7.5 mm
for the right lateral direction, 6.1 ± 11.6 mm for the superior
direction and 5.0 ± 11.2 mm for the inferior direction.18 Mae-
moto et al. also determined the predictive factors affecting
uterine movement during definitive radiotherapy (RT), they
compared interfraction uterine movement using pre-RT
planning CT (n = 38) and intratreatment CBCT (n = 315). The
mean corpus movement was: superior margin (SI direction),
7.6 ± 5.9 mm; anterior margin (AP direction), 8.3 ± 6.3 mm;
left margin (ML direction), 3.3 ± 2.9 mm; and right margin
(ML direction), 3.0 ± 2.3 mm. They also observed a significant
correlation between changes in bladder volume and the
movement of the superior margin of the corpus ( = 0.364,
P < 0.001). Additionally, there was a significant difference in
movement of the superior margin of the corpus between
the subgroups with and without a history of previous pelvic
surgery (not related with cervical cancer) (P = 0.007). They
concluded that changes in bladder volume and a history of
previous surgery were significantly related to intrafractional
corpus movement.19 Other authors also highlighted the filling
volume of the bladder as the principal cause of altering the
position of the uterus, especially in the AP and SI directions.
With variable bladder filling, ranges of uterus motion goes to
of 5–40 mm in the SI and 0–65 mm in AP directions.10,17,18
A notorious aspect in uterus movement is the extreme dis-
placement of the fundus and the rotations of the uterus angle.
Fundus moves up to a maximum of 48 mm in the AP direction
in some series and is the part of the uterus with the largest
movements. Uterine rotation was reported up to 91◦ and in
some patients the uterus can turn from anteverted to retro-
verted during the treatment, especially in patients under 60
years of age.17
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Lymph nodes: Lymph nodes contract and change position in
an important range. Reports evaluating ganglion movements
had been made. A median of translations oscillating between 7
and 30 mm have been found, suggesting inhomogeneous mar-
gins of 5–9 mm to cover 95% of the volumes.10,20 Schippers
et al. measured the contraction of the pelvic and para-aortic
nodes using MRI. During treatment weeks 1–3, nodal volumes
increased, compared with pre-treatment scans, but in week 4
almost all the nodes had regressed by 58% on average.21
2.1.2. Organs at risk variations
Preservation of organs at risk (OAR) is the priority in radio-
therapy treatments and is the principal reasons to use highly
conformal treatments like IMRT. The dosimetric benefits for
the small intestine, bladder, rectum, and bone marrow in
cervical cancer treatments are big, but the non-orchestrated
motion of all these organs makes clinical execution difficult.12
Bladder: The bladder undergoes continuous changes dur-
ing treatment which affects the organ itself as well as the
target volume and/or other organs. In 2009, Beadle et al.
observed that normal variations in bladder volume could have
a profound influence on the location of the cervical target.
Comparisons between full-bladder and empty-bladder scans
obtained on the same day showed variations in cervix perime-
ters up to 1.5 cm.22 Subsequent reviews have shown that filling
the bladder has less impact on the movement of the cervix
than uterus. Variability in bladder filling was measured by Tay-
lor et al. who found that if volume varies less than 50 ml, the
average uterine motion is 4.2 mm, compared with 11.2 mm if
variation is larger than 50 ml.17
The relationship between the filling of the bladder and the
position of the small intestine is frequently seen in clinics.
Large bladder volumes displace the small intestine out of the
targets causing a reduction in its irradiated tissue. A reduction
of about 83 ml (range 0–292 ml) of small intestine was observed
by Georg et al. for doses of 50 Gy and 51 ml (range 0–172 ml) for
doses of 45 Gy.15
When comparing average bladder volumes during the first
five sessions with those of the last five sessions significant dif-
ferences are seen. An important reduction in bladder capacity
has been reported, possibly explained by the onset of radia-
tion cystitis. The average bladder volume in the first week was
156 cc vs. 88 cc in the last week of treatment; the reduction
in bladder capacity impact the uterus motion producing an
average motion at the uterine fundus of 18 mm, at the uterine
canal 8 mm, and at cervix of 3 mm for every 10 ml decrease.10,18
Eminowicz et al. also reported data about changes in bladder
filling. They analyzed 10 cases of cervical cancer, finding that
the volume of the bladder during radiotherapy was between
45 and 578 ml, while at the planning it was larger, between 73
and 664 cm3. The volume of the bladder increased 4 ml/min
with the waiting time, decreased on average 4 ml/day during
the treatment and was higher (50 ml) along the chemother-
apy period. If the difference in volume is greater than 130 ml,
the probability that the PTV cover the CTV is reduced by 1.9%.
Additionally, if the bladder has a volume higher than 300 ml,
it is not possible to reproduce it during the treatment.23
Rectum: Changes in rectal volume have a significant rela-
tion with the displacement of target volumes-especially GTV
– because rectal filling has a greater influence on cervix and
superior vagina position. An analysis performed by van de
Bunt et al., using serial MRI, showed a significant correla-
tion between weekly changes in rectal filling and shifts of the
GTV in AP direction (P < 0.001). No significant correlations have
been observed in the other directions, although SI shifts were
also described. Displacements of the CTV in AP and SI direc-
tion were found, but the correlations with the rectum was
weak.14
Daily variations in rectal filling has been described by sev-
eral authors. An average rectal volume at start of treatment
of 58 ml (range, 35–88 ml) was reported by Collen et al. van
de Bunt et al. reported an average rectum volume of 78 ml
(25–143 ml), median volume 69 ml; while Jadon et al. collected
ranges of 21–150 ml. However, all authors agree that there are
no significant differences in rectal filling volume between the
start and end of treatment, neither systematic changes.10,14,18
In regards to the measurements within the anteroposterior
diameter of the rectum, Eminowicz et al. showed interest-
ing data. They reported an inverse relationship between rectal
anterior-posterior diameter and bladder volume. The coverage
of CTV1 (uterus and cervix) was unsatisfactory with AP diam-
eter >4.5 cm vs. 3.6 cm. The possibility that the PTV covered
the entire CTV was reduced by 5.8% with each mm of devia-
tion of the rectum in the AP direction. At the same time, this
probability is greater if the rectum is wider in the treatment
than in the simulation.23
2.1.3. Reduction in tumor volume and shape deformation
Reduction in tumor volume as tumor response, is a deter-
mining effect because it drastically alters the position of
organs and structures between each other. In their study of
16 patients with locally advanced cervical cancer, Chen et al.
observed that the volume and location of the cervix changed
significantly during the course of treatment, and concluded
that tumor regression occurs mainly between the second and
third week of treatment, needing an adaptive new treatment
plan.24 Table 1 depicts some of the cervix shrinkage values
reported in literature.
There are also changes in organs shape, especially in uterus
and in bladder capacity filling (elsewhere explained here).
Bondar et al. analyzed a series of patients in an attempt
to predict the variation in shape of the uterus, concluding
that it is possible to predict the position and shape of the
uterus if the volume in the bladder is known/controlled. As
described above, the uterus changes from anteverted to retro-
verted, as well as remarkable rotations are possible during
treatment.17,24,25
2.2. Planning target volume considerations
Once ITV is known, an additional margin is required. The
planning target volume (PTV) should include additional uncer-
tainties. Dosimetric uncertainties and setup errors must to be
considered in addition to organ motion and shape variations
considered in ITV.26
Dosimetric uncertainties (penetration of beam, beam
geometry, calculation algorithm) are a complex aspects in
radiotherapy which can affect the treatment delivery and
reproducibility; however, its analysis is beyond the scope
of this review. Its knowledge, adjustments and possible
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Table 1 – Sample of papers describing cervix shrinkage.
Author Measuring tolls Measurement time Reduction value
Beadle et al.22 TC scan (weekly) 45 Gy 97 ml to 31.9 ml, mean volume reduction 62.3%.
Lee et al.8 Clinically, bimanual examination 30.8 Gy 50% reduction
Chen et al.24 CBCT (weekly) 48.6 Gy 79.62 ml to 20.86 ml
problems are the matter of physicist team at IMRT/IGRT
protocol developing.
Setup errors are defined as the differences between the
planned position and the position during delivery. They
occur due to variations in fixation systems and/or patient’s
tatoo alignment, mechanical mismatches (laser miss aligning,
couch rotation, etc.), staff expertise and time available to do
the positioning.26 A useful description of this kind of errors
in pelvic radiotherapy is made by Kim et al., when analyzing
52 patients treated with IMRT or 3D conformal radiotherapy.
Using 2D kV images and/or CBCT, they compared planned vs.
on-treatment images finding a systematic and random errors
of 1.1 mm, 2.3 mm, 2.3 mm and 3.9 mm, 5.0 mm, 3.5 mm in AP,
ML and SI directions, respectively, suggesting a setup mar-
gin for CTV to PTV of 5.5, 9.1 and 8.3 mm in AP, ML and SI
directions, respectively.27 Besides 3D vector variation, rota-
tional shifts have been identified. A retrospective analysis was
made in 25 cervical cancer patients treated with IMRT radio-
therapy for cervical cancer into EMBRACE protocol; at the end
of the treatment, Laursen et al. analyzed the residual rotation
error through a comparison using the CBCTs made during the
treatment. A mean and standard deviation for the residual
rotational errors obtained through retrospective offline regis-
tration were 0.04◦ ± 1.40◦, −06◦ ± 0.9◦, and 0.04◦ ± 0.9◦ for pitch,
yaw and roll, respectively, resulting in a target shift larger than
5 mm in 57 of the 650 treatments evaluated.28 A demonstra-
tion of how this setup errors can affect the clinics was reported
by Xin in 170 cervical cancer patients; all these patients under-
went pelvic IMRT, but in a group of 86 patients a strict CBCT
protocol was conducted and shifts corrected online, getting a
significant reduction of comparative toxicity.29
3. IGRT solutions
Many studies relevant to IGRT have been published which offer
different solutions to reduce the risk of geographical failure,
as well as decrease the inclusion of unnecessary healthy tis-
sue. Consequently, IGRT is, above all current methods, the
best strategy to reduce setup uncertainties, if accompanied
by adequate patient preparation, reproducible positioning,
appropriate margins, the use of verifying images during treat-
ment and fiducial placement.
3.1. Preparation
There is scarce literature about recommendations related
to the preparation of patients for virtual simulation and
treatment. Eminowicz et al. conducted a retrospective study
in which they suggest bladder and rectal filling volumes
and timing for verifying images. An ideal planning volume
for the bladder will be between 150–300 ml, achieved by the
authors with 3 cups of water and 30 min of waiting time, but
they considered shortening it to 20 min in the days of con-
comitance. Additionally, they suggest an adequate hydration
throughout the entire treatment. Regarding rectal prepara-
tion, they found the administration of laxants for planning
and during the entire treatment to be useful, depending on
Bristol stool scale (type 1–3 twice daily laxant, 4–5 once a day,
6–7 no laxant). If a rectal diameter is more than 4 cm, micro
enemas should be used. However, these measures are not
enough without the regular verifying images.23 Previously,
Chan’s protocol had proposed to evacuate urine 1 hour before
each scan and treatment, followed by the intake of 500 ml of
water to achieve a reproducible bladder filling. For rectal repro-
ducibility they also recommend administration of magnesium
hydroxide the night before, unless GI toxicity exist.9
3.2. Positioning
The use of conventional techniques, prone position and Belly
Board (BB) have been considered a strategy to reduce irra-
diation of the small intestine volume (SIV). Hence, some
authors have compared this to the supine position using IMRT
techniques, highlighting Adli et al. and Stromberger et al. stud-
ies. They reported a reduction in SIV receiving more than
45 Gy, from 19 to 12.5% and 20.3 to 13.7%, respectively, but
with an increase of 9.9% of the large intestine and rectum
irradiated.30,31 In 2012, Wiesendanger-Wittmer et al. reported
the impact of the position and the BB in a systematic review
of the literature on pelvic tumors. This review shows that the
prone position contributes to diminishing SIV irradiated when
compared with the supine position, being even greater when
BB is added. A theoretical impact could be expected on a reduc-
tion of GI toxicity.32 Additionally, other systems have been
developed to displace the small intestine, based on compres-
sion with Styrofoam, and are also used in conjunction with
the prone position and the BB, reducing the SIV between the
PTV from 67.9 to 16.8% (P 0.00002). No changes in the rectum or
bladder were seen, when the IMRT technique was added.33,34
3.3. Margins
In a review by Jadon et al., internal margins were proposed
in order to assure movements of the cervix.10 Data from
nine studies with 176 patients were summarized. In some
of these publications isotropic margins between 15.3 and
21 mm around the CTV are suggested, but most of them pro-
posed anisotropic margins from 12 to 32 mm on the AP axis,
8 to 20 mm SI and 7 to 17.5 mm ML (Table 2). All of these
publications used different imaging modalities at different
moments.9,14,16–18,20,33,35,36
Van de Bunt et al. showed statistically significant differ-
ences between patients’ rectum filling above and below 70 ml,
































Table 2 – Proposed margins summary.




Collen 2010 0.4 ± 10.1f 3 ± 6.9f 2.2 ± 8f 0.5 ± 5f 3.5 ± 4.9f 0.2 ± 4.5 0.2 ± 2.3e 1.1 ± 1.3e −0.3 ± 1.6e
Patnj 2017 10.3 5.8 5.6
Maemoto 2017 3.3 ± 2.9 3.0 ± 2.3 7.6 ± 5.9 8.3 ± 6.3
Wang 2012 4a 19b 5a 32b
Chan 2008 0.45a 15b 10a 40b
Schippers 2014 7c 8c 7c 9c 7 medial and 4 lateralc
Van de Bunt 2008 12f 24d 14f 17d 4f 11d 8f 8d 11f 16d 12f 12d
Tyagi 2011 15 around CTV
Taylor 2008 15d 15d 7d 7c
Lim 2009 5 from PTV with daily IGRT
Williamson 2016 15 CTV110 CTV25–7 CTV 3
Velema 2012 >10c
Kim 2011 7c
Khan 2012 20d 10d 10d 10d 10d 10d 13d
a Isotropic margin intrafraccion.





CTV1: GTV + cervix + uterus.
CTV2: parametria + upper half vagina.
CTV3: pelvic nodes.
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proposed a 5 mm margin at the body and 4 mm at the cervix,
in order to include 95% of the CTV during intrafraction move-
ment while wider margins of 32 mm (body) and 19 mm (cervix)
are required for interfraction changes. This way, PTV must
expand respectively to include these uncertainties.16 Chan
et al. suggested broader margins of up to 4 cm in the uter-
ine fundus and 1.5 cm in the exocervix to ensure interfraction
movements and 1 cm and 0.45 cm intra-fraction, respectively,
with daily soft-tissue imaging to correct for interfractional
motion or adaptive replanning.9 Taylor et al. proposed an
asymmetrical margin with CTV–PTV expansion of the uterus,
cervix and upper vagina of 15 mm AP, 15 mm SI and 7 mm lat-
erally and expansion of the nodal regions and parametria by
7 mm in all directions.17
Moreover, Tyagi et al. showed how a 15 mm isotropic mar-
gin failed to encompass the entire CTV in 32% of the fractions.
However, the mean volume ‘missed’ was 4 ml.35 A further vir-
tual study modeled three scenarios, with results favoring a
tapered CTV-to-PTV margin that increases around the fundus.
This would restore fundus and CTV dose to desired levels, but
would increase normal tissue volumes receiving doses in the
range 30–50 Gy by a further ∼5%. In sum, when uterine motion
is large and compensated for with a tapered margin, normal
tissue volumes receiving doses in the range 30–50 Gy increase
by up to 13%.37
Conversely, Lim et al. suggested a 5 mm margin allowed for
pelvic organ motion with adequate dose delivered to 98% of
the CTV in 95% of patients. But, one patient had significant
underdosing due to unpredictable target motion.13 Moreover,
Williamson et al. tried to validate models to justify strategies
to define PTVs. Their results showed that 95% isodose line
completely encompassed 92.3% of all CTVs (95% CI 88.3–96.4),
not significantly different from the 95% probability anticipated
a priori (P = 0.19). The total proportion of missed CTV was
small, mostly the mean of covered CTV was 99.9%, and 95.2%
misses were located in the anterior body of the uterus. So,
definitely, with the clinical implementation of a previously
proposed PTV definition strategy based on a shape model
for intact cervical cancer, the probability of CTV coverage
was high and the volume of CTV missed was low. This PTV
expansion strategy is acceptable for clinical trials and prac-
tice; however, they recommend daily image guidance to avoid
systematic large misses in select patients.38
Regarding nodal internal margins, evidence is scarce.
Velema et al. mentioned that with the current clinical margin,
adequate coverage of the nodal CTV cannot be guaranteed
for all patients. These findings emphasize the need to deter-
mine accurate CTV-to-PTV margins for the nodal CTV in
highly conformal IMRT of cervical cancer patients.39 In their
paper, Schippers et al. reported pelvic and retroperitoneal
nodes motion. Seventeen patients with visible nodes on MR
images underwent T2-weighted MR scans before and weekly
during the course of IMRT. Nodal volume regression from
the pre-treatment condition to week 4 was 58% on average
(range: 11.7% increase to 100% decrease). Nodal volumes
partly increased between the pre-treatment scans and the
scans in weeks 1–3, but in week 4 all nodes except one had
regressed. Around the nodal volumes manually derived ITV
margins accounting for volume changes and position shifts
of 7.0, 4.0, 7.0, 8.0, 7.0 and 9.0 mm to the medial, lateral,
anterior, posterior, superior and inferior directions were
needed to cover 95% of all nodes. These margins should
be taken into consideration when planning external beam
radiotherapy (EBRT) boosts, especially for highly conformal
boosting techniques. With these contradictory information,
a 1 cm margin is deemed as sufficient in one study and
insufficient in another.21 Consensus guidelines, still, suggest
a 7 mm CTV to PTV margin for nodal volumes.7
Another strategy was proposed by Khan et al. to optimize
PTV margin. Using data from CT planning and CBCTs, they
modeled the CTV variations; 758 landmarks were placed over
the planning CTV and vectors from these superimposed on
CBCTs, so PTV definition according to surface marking led to
improving CTV coverage with narrow PTV margins.40
3.4. CBCT
CBCT images and MVCT are the most commonly used IGRT
systems in clinics. Collen et al. took MVCT to measure changes
in the cervix, such as an average and standard deviation by
anterior 0.4 mm ± 10.1 mm, posterior −3 mm ± 6.9 mm,
superior 2.2 mm ± 8 mm, inferior 0.5 mm ± 5.0 mm, left
3.5 mm ± 4.9 mm and right 0.2 mm ± 4.5 mm. Variations at
the uterine level were greater as discussed above. From their
experience, they suggest daily use of MVCT, as an alternative
that allows to make adjustments in the positioning.18
Another recommendation is to perform at least CBCT once
a week for organ motion monitoring plus daily verification of
bladder filling with a bladder scan or CBCT if bladder scan is
not available.23
In addition, a study carried out with 105 patients with gyne-
cological malignancies assessed CBCT once a week for IMRT
and daily for IGRT/VMAT. A total of 2078 CBCT images were
studied. The margins of PTV volume were calculated from
the variations in the setup. The setup variation was 5.8, 10.3,
and 5.6 mm in AP, SI, and ML direction. This allowed adequate
dose delivery to the CTV and the sparing of organs at risk.
The researchers concluded that daily kV-CBCT is a suitable
method of accurate patient positioning with high-precision
techniques, preventing geographic miss.26
3.4.1. Fiducial markers
Implanted fiducial markers (FM) can facilitate fast detection
of interfraction and intrafraction tumor motion in the treat-
ment of cervical cancer. Previous experiences with implanted
markers in the cervix were characterized by the loss of mark-
ers and the presence of significant scatter artifacts in CT scans;
marker loss rates of 14–42% were found using a fluoroscopic
electronic portal imaging device (EPID) and radiopaque mark-
ers to detect internal cervix movement.41 FM (tantalum, gold
and polymeric) were used in five studies. Good marker visu-
alization was reported with planar kilovoltage imaging (90%
visualized) and CBCT (100%).10 Mens et al. placed 4 to 6 poly-
meric markers in the fornices of the vagina. It turned out to
be a very reliable method with hardly any marker loss dur-
ing RT and with a marker localization between 90% and 100%
in the kV images and CBCT, respectively. Even after cervix-
uterus is shrunk, a constant distance was maintained between
the individual markers and the surface of the cervix uterus.
These led them to suggest that this is a reliable method to
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track inter and intrafraction motion during treatment.42 More-
over, cervix interfraction motion was measured in fifty cervical
cancer patients assessed by daily CBCT imaging with a new
polymeric marker. They evaluated visibility, artifacts and FM
loss. First, sufficient visibility of the markers was verified.
Streaking artifacts for the new markers were reduced com-
pared to conventional gold markers. Marker loss was minimal
during treatment: in only 3 of the 50 patients, one marker
was lost. Second, systematic and random displacement of the
marker was recorded and analyzed in three dimensions with
regard to the planning CT and the first CBCT, showing similar
displacement with respect to other published data and good
reproducibility.11
3.4.2. Adaptation
Adaptive radiotherapy plans seem to be essential in tar-
gets with large variability because of rapid tumor response,
changes in size and/or organ motion. Cervix cancer is a good
example of it.
Lee et al. described how carcinoma of the cervix involutes
rapidly with chemoradiotherapy and high dose rate (HDR)
brachytherapy. The time for 50% tumor regression was cal-
culated to be 21 days and occurs after 30.8 Gy.8
In 2011 and 2012 Bondar’s papers individualized model-
based ITV accounting for the cervix and uterus motion.
Bladder volume changes were generated by using a motion-
model constructed from two pretreatment CT scans (full and
empty bladder). For the majority of patients, the anticipated
error was below the margin encompassing the cervix-uterus
motion; the population-based approach was 38 mm and 7 to
10 mm for the individualized strategies. This strategy could
be used to create a patient-specific ITV and to support online
adaptive strategies.25,43
Based on their previous findings, the concept of plan of the
day was introduced by the same group. Thus, the creation of a
plan library per patient is based on the choice of an appropriate
plan for every treatment session based on the imaging of each
day. In other words, plan libraries were generated using scans
with variable bladder filling (and hence different uterine posi-
tions) and the plan of the day chosen was based on bladder
volume. Adaptive approach was reproducible and increased
OAR sparing, compared with non-adaptive methods.44
More recently, Chen et al. found significant variations in
tumor regression and spatial location occurred during treat-
ment. GTV decreased during the course of radiation therapy
(P < .001) from 79.62 ml at prior treatment to 20.86 ml at the
end of external radiotherapy. CTV changed to some degree
from 672.59 ml to 608.26 ml, and the uterine volume (UV)
changed slightly from 83.72 ml to 80.23 ml. The mean per-
cent volume changes ranged from 23.05% to 70.85% for GTV,
4.71% to 6.78% for UV, and 5.84% to 9.59% for CTV. Changes
in GTV-correlated with the RT (P < .001). Actually, adaptive
radiotherapy approaches are necessary to improve treatment
accuracy for cervical cancer.24
These data indicate that adaptation is a possible solution
and an important strategy to ensure accuracy with less-
toxicity treatment.
3.4.3. Other potential solutions
As far as we know, no study has directly compared offline
versus online imaging strategies for the management of organ
motion. Taking into account the large interfraction variability
reported in the literature, an offline review does not seem to
be appropriated to correct at the right moment possible setup
shifts.
In addition, uterine sleeve placement allowed to document
the median and maximum ranges of cervical mobility dur-
ing the treatment course of RT to be 8–16 mm and 23–36 mm,
and at the time of HDR brachytherapy to be 5–12 mm and
11–32 mm, respectively.8,45 Furthermore, Jan et al. data about
sleeve application during the course of thomotherapy and
brachytherapy could be used as a surrogate marker for local-
ization of the tumor before daily IGRT.46
Lou et al. documented comparisons of bladder scanner
(BS) with CT, CBCT, and an ultrasound diagnostic device
(iU22). A consistent and reproducible bladder volume (BV)
is acquired by using a portable BS. Hence, the target dis-
placement and CTV-to-PTV margin can be both reduced in
the supero inferior direction but had little or no effect in
the anterior–posterior and right–left directions. With BS the
BV deviated by 1.4% in accuracy. There were no difference
between the measurements of the BS and the iU22. The BV
measured by the BS was strongly correlated with actual urine
volume, as well by CT or CBCT, P < 0.05. The BV increased
by 3.7 ± 1.0 ml/min, which depended on the amount of water
ingested by the patient (R = 0.96, P < 0.05). The authors were
able to reduce the workload related to the measurements by
using individual patient information including the patient’s
age, water-drinking amount, time at which water-drinking
began, and patient’s diet.47
4. Discussion
This non-systematic review summarizes relevant data pub-
lished from three level of evidence which highlights the
challenges facing cervical IMRT treatment, such as cervi-
cal/uterine motion, reduction of GTV as tumor response and
the impact of bladder and rectal filling. The purpose is to offer
a general vision of the main steps to be taken into account by
each clinical facility wanting to introduce this technology.
Selection of appropriate contours and margins is manda-
tory. In the majority of the studies reviewed, margins were
presented only in terms of PTVs, although, all of them
explained and measured internal organ motion as well as set-
up uncertainties. We rather present margins in terms of ITV
and PTV separately, as a way to emphasize the importance of
position displacements, changes in alignment, beam geome-
try and all the other setup uncertainties different from organ
motion. Even though these aspects were not treated in depth;
identifying, measuring and correcting them, should be a prior-
ity when establishing IGRT local protocols. However, designing
an ITV is optional if PTV includes “all” uncertainties.48 Def-
initely, the margins are affected more by the movement of
the uterus than by the movement of the cervix, because the
uterus is more prompt to rotational and translational changes
in greater proportions. Some data indicates a maximal AP uter-
ine motion of 48 mm and 32 mm in SI direction.17 Interfraction
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motion is more pronounced than intrafraction motion, but
both most be taken into account within ITV margins. There-
fore, based on this information, a larger uterine margin and a
smaller cervical margin, would probably include the different
movements described.
Bladder filling has more impact on uterine motion and rec-
tal filling more impact on cervical and vaginal motion. During
treatment, bladder undergoes changes in daily volumes and
filling capacity. Thus, patients with bulky locally advanced
tumors could have difficulties in bladder filling (Fig. 1, DICOM
files). We have not found reports about how these aspects
affect the bladder itself, in terms of radiation exposition and
risk of toxicity. A full bladder could have an advantage in
decreasing its mean dose and V45–50, but it is not repro-
ducible. An empty bladder is more reproducible, but would
imply the opposite, in terms of dose exposition. According to
this, a comfortably full bladder could have clinical and dosi-
metric benefits to protect the organ itself, as well as sparing
doses at intestine and rectum.
Gynecological radiotherapy treatments are carried out in
a prone or supine position. There is no rule, but a prone
position is normally recommended in postoperative scenario
while supine is used in primary treatments. The advantages
of one over the other seem to be greater for 3D conformal
radiotherapy than for IMRT.32 In the literature reviewed and
commented in this paper, there are no firm recommendations
of one or the other. In fact, the measures and analysis pre-
sented by the authors deal with patient positioning, both in
prone and supine (some did not even mention it). We identified
a relatively greater number of patients positioning in supine
but it is not possible to make any analysis or recommenda-
tion based on this. We consider supine position superior in
terms of reproducibility, patient’s comfort and is easier for
the staff to evaluate organ motion or filling. The dosimetric
advantages of prone position in terms of intestine dose spar-
ing are at the expense of greater dose in rectum; although the
intestine is more sensitive to radiation damage, the rectum is
closer to the targets and is exposed throughout the treatment
(even at brachytherapy). We reserved prone position in pri-
mary treatment of cervical cancer, just when intestine doses
are not controlled by bladder filling and IMRT/IGRT solutions
at supine position.
Even though FM had demonstrated adequate reliability
in clinical practice, they only identify the upper vagina and
cervix position but not represent the motion of the other
pelvic organs and targets (parametrial tissue, uterus, gan-
glia, bladder, etc.).41 Because of the complexity described
in pelvic IMRT, we do not recommend FM alone as a IGRT
solution. CBCT permits a more complete evaluation of all
pelvic organs, thanks to its ability to show soft tissue in
addition to bone and/or FM. Patient positioning, setup dis-
placement, bladder and rectal filling and target motion can
be evaluated easily with this IGRT solution. Perhaps, CBCT
has a limitation in time of execution, staff training and
intrafractional tracking, that can be improved by combining it
with FM. CBCT alone, or in combination with FM are the most
widespread and complete IGRT solutions to put into daily
practice.
Defining the adequate margins to CTV-ITV-PTV is proba-
bly the most difficult and relevant task in the preparation of
IGRT protocol. Thus, we found it hard to summarize all exist-
ing information on this topic. We found a lot of heterogeneities
between the different consulted papers: time to do the mea-
sures, techniques used, methodology to measure and/or to
analyze data; patient’s race, patient’s age, clinical tumor stage,
position at the couch and technology available, among oth-
ers. We can just suggest 2 things after our own analysis: 1.
Anisotropic margins: in trying to choose not to narrow, not to
large margins, it is a fact that each CTV and organs inside the
pelvis have a different range of motion to take into account in
ITV; 2. Select and review by your own the literature which best
suits your population and facility aspects at the time of choos-
ing your margins. Our review is not a systematic one, which
poses a certain limitation. We performed a detailed search
in databases and included the only one systematic review
found that suits our parameters. Nevertheless, some useful
studies may have been omitted here. Supported by all data
presented, but based on our interpretation, and on our own
experience and practice, we offer our recommendations in
Table 3.50
We think that modifications in contouring guidelines
could be required to facilitate the implementations of
anisotropic/asymmetrical margins in clinics. Perhaps, defin-
ing a high risk CTV (HR-CTV) for IMRT/IGRT treatments
including GTV and the entire cervix, as in brachytherapy
contouring guidelines, could be practical. It would allow sep-
arating the uterus (the most mobile target) from CTV1 and
creating a different volume to it, therefore, different ITV mar-
gins to cervix and uterus. In addition, an HR-CTV could be
useful at the time of brachytherapy to analyze and compare
plans, doses, tumor shrinkage and areas at risk, among others.
A consensus guidelines is expected, which will have to
include recommendation about minimum equipment, qual-
ity assurances, contouring and safety margins. At the moment
IGRT/IMRT is not the standard on practice, so randomized tri-
als on adative IGRT/3D versus IGRT/IMRT are also required.
Table 3 – Authors recommendation.
Recommendation
Position Supine. Better reproducibility, patient comfort.
Bladder filling Comfortably full bladder. Drink 500 ml of water and wait 30 min
Rectum preparation Empty rectum. Transverse diameter <4 cm. Oral laxative and/or microenemas according to Bristol stool chart []
TC planning TC with empty and comfortably full bladder.
Contouring Contour ITV to CTV1 using both TC planning.
Adaptive Re-planning at 3th treatment week. Significant tumor and ganglia shrinkage.
Technique Volumetric IMRT (VMAT). Faster delivery = less intrafraction motion.
IGRT solution Daily CBCT. Optional: add FM.





Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at https://doi.org/
10.1016/j.rpor.2018.05.002.
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